Caption Management’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$243M Buy
410,000
+250,200
+157% +$125M 1.42% 8
2025
Q4
$77.9M Sell
159,800
-150,000
-48% -$69.9M 0.53% 34
2025
Q3
$130M Buy
309,800
+246,600
+390% +$82.9M 1.01% 11
2025
Q2
$18.2M Buy
63,200
+19,400
+44% +$5.8M 0.2% 99
2025
Q1
$13.5M Buy
43,800
+23,800
+119% +$8.16M 0.13% 143
2024
Q4
$7.06M Buy
+20,000
New +$7.35M 0.07% 273
2024
Q3
Sell
-20,000
Closed -$6.37M 1599
2024
Q2
$6.37M Buy
+20,000
New +$5.29M 0.1% 219
2023
Q4
Sell
-15,000
Closed -$3.39M 1700
2023
Q3
$3.39M Hold
15,000
0.05% 439
2023
Q2
$3.31M Buy
+15,000
New +$3.32M 0.06% 381
2022
Q4
Sell
-100,000
Closed -$20.9M 1745
2022
Q3
$20.9M Buy
100,000
+80,000
+400% +$17.9M 0.29% 63
2022
Q2
$4.71M Buy
+20,000
New +$4.07M 0.07% 366
2022
Q1
Sell
-20,000
Closed -$4.32M 1974
2021
Q4
$4.32M Sell
20,000
-34,000
-63% -$6.67M 0.05% 501
2021
Q3
$9.97M Buy
+54,000
New +$10.6M 0.11% 236
2019
Q4
Sell
-25,000
Closed -$1.99M 1014
2019
Q3
$1.99M Buy
+25,000
New +$2.01M 0.1% 239

Other funds holding UTHR

Caption Management's UTHR Position: Q1 2026 in Review

Caption Management increased its United Therapeutics (UTHR) stake by 35% in Q1 2026, buying an estimated $9.64M and bringing the position to 74,445 shares worth $44.1M. The position accounts for 0.26% of the portfolio, ranked #75.

Caption Management first reported a position in UTHR in Q3 2021 and has held it in 7 quarters since. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Caption Management held 74,445 shares of United Therapeutics worth $44.1M as of Q1 2026.
  • Caption Management bought 19,364 United Therapeutics shares in Q1 2026, an estimated $9.64M.
  • United Therapeutics made up 0.26% of Caption Management's portfolio in Q1 2026, its #75 holding.
  • Caption Management first reported a position in United Therapeutics in Q3 2021 and has held it in 7 quarters since.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.